https://en.bioecon.ru/companies/crispr-therapeutics/Recent content in Crispr-Therapeutics on BioeconHugoen-USWed, 29 Jul 2026 13:42:49 +0700https://en.bioecon.ru/technology/genome-editing/Wed, 24 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/genome-editing/Programmable genome editors — CRISPR-Cas9, base editors and prime editors — delivered ex vivo or in vivo via lipid nanoparticles to treat genetic disease, from the first approved CRISPR therapy Casgevy to in-vivo redosable CRISPR and single-dose cardiovascular base editing.https://en.bioecon.ru/technology/personalized-regenerative-medicine/Fri, 19 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/personalized-regenerative-medicine/Gene and cell therapy platforms for rare monogenic and oncological diseases: AAV vectors, lentiviral HSC editing, ex vivo CRISPR (Casgevy) and in vivo CRISPR (LNP delivery) now deliver durable one-time treatments approved by FDA and EMA.